Skip to main content
SpringerLink
Log in

PET in Lung Cancer and Mediastinal Malignancies

  • Chapter
  • First Online:
Clinical Nuclear Medicine

  • 1361 Accesses

Abstract

FDG PET/CT plays a major role in the clinical management of lung cancer. Its main uses are staging of non-small cell lung cancer (NSCLC) and characterization of solitary pulmonary nodules (SPM). Furthermore, it can be employed for staging of small cell lung cancer (SCLC) and for recurrence detection. Other thoracic malignancies accessible to FDG PET/CT are malignant pleural effusion, pleural mesothelioma, and thymic epithelial tumors (TETs). This chapter gives an overview of the diagnostic work-up of patients with these malignancies with special focus on the clinical significance of FDG PET/CT in relation to other imaging modalities such as diagnostic CT and MRI and its significance to guide clinical algorithms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

    Article  Google Scholar 

  2. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors. J Thorac Oncol. 2015;10:1243–60.

    Article  Google Scholar 

  3. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1–iv21.

    Article  CAS  Google Scholar 

  4. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697–722.

    Article  Google Scholar 

  5. Furtado CD, Aguirre DA, Sirlin CB, et al. Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology. 2005;237:385–94.

    Article  Google Scholar 

  6. Sim YT, Poon FW. Imaging of solitary pulmonary nodule-a clinical review. Quant Imaging Med Surg. 2013;3:316–26.

    PubMed  PubMed Central  Google Scholar 

  7. Gould M, Maclean C, Kuschner W. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914.

    Article  CAS  Google Scholar 

  8. Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007;48:214–20.

    PubMed  Google Scholar 

  9. Barger RL, Nandalur KR. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol. 2012;19:153–8.

    Article  Google Scholar 

  10. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Chichester: Wiley Blackwell; 2016.

    Google Scholar 

  11. Hellwig D, Baum RP, Kirsch CM. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin. 2009;48:59–69.

    Article  CAS  Google Scholar 

  12. De Wever W, Vankan Y, Stroobants S, et al. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J. 2007;29:995–1002.

    Article  Google Scholar 

  13. Wu Y, Li P, Zhang H, et al. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer. 2013;132:E37–47.

    Article  CAS  Google Scholar 

  14. Goeckenjan G, Sitter H, Thomas M, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie. 2010;64(Suppl 2):e1–164.

    Google Scholar 

  15. Gregory DL, Hicks RJ, Hogg A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53:1007–15.

    Article  Google Scholar 

  16. Kalemkerian GP. Staging and imaging of small cell lung cancer. Cancer Imaging. 2011;11:253–8.

    Article  Google Scholar 

  17. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338–45.

    Article  CAS  Google Scholar 

  18. Jiménez-Bonilla JF, Quirce R, Martínez-Rodríguez I, et al. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT. Lung Cancer. 2013;81:71–6.

    Article  Google Scholar 

  19. Jimenez Bonilla JF, Quirce Pisano MR, Martínez Rodríguez MI, et al. The role of PET/CT molecular imaging in the diagnosis of recurrence and surveillance of patients treated for non-small cell lung cancer. Diagnostics. 2016;2016(6):36.

    Article  Google Scholar 

  20. Nakajima R, Abe K, Sakai S. Diagnostic ability of FDG-PET/CT in the detection of malignant pleural effusion. Medicine (Baltimore). 2015;94:e1010.

    Article  Google Scholar 

  21. Marel M, Zrustova M, Stasny B, et al. The incidence of pleural effusion in a well-defined region: epidemiologic study in Central Bohemia. Chest. 1993;104:1486–9.

    Article  CAS  Google Scholar 

  22. Porcel JM, Hernández P, Martínez-Alonso M, et al. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2015;147:502–12.

    Article  Google Scholar 

  23. Kruse M, Sherry SJ, Paidpally V, et al. FDG PET/CT in the management of primary pleural tumors and pleural metastases. Am J Roentgenol. 2013;201:W215.

    Article  Google Scholar 

  24. Yildirim H, Metintas M, Entok E, et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol. 2009;4:1480–4.

    Article  Google Scholar 

  25. Benard F, Sterman D, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713–22.

    Article  CAS  Google Scholar 

  26. Elliott HS, Metser U, de Perrot M, et al. 18 F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center. Br J Radiol. 2018;91:20170814.

    Article  Google Scholar 

  27. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg. 2005;129:1364–70.

    Article  Google Scholar 

  28. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg. 2004;77:1860–9.

    Article  Google Scholar 

  29. de Jong WK, Blaauwgeers JLG, Schaapveld M, et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2008;44:123–30.

    Article  Google Scholar 

  30. Girard N, Ruffini E, Marx A, et al. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v40–55.

    Article  Google Scholar 

  31. Treglia G, Sadeghi R, Giovanella L, et al. Is 18F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? A meta-analysis. Lung Cancer. 2014;86:5–13.

    Article  Google Scholar 

  32. Nakagawa K, Takahashi S, Endo M, et al. Can 18F-FDG PET predict the grade of malignancy in thymic epithelial tumors? An evaluation of only resected tumors. Cancer Manag Res. 2017;9:761–8.

    Article  Google Scholar 

  33. Passuello N, Pozza G, Blandamura S, et al. Thymoma metastatic to liver and pancreas: case report and review of the literature. J Int Med Res. 2017;45:868–74.

    Article  Google Scholar 

  34. Otsuka H. The utility of FDG-PET in the diagnosis of thymic epithelial tumors. J Med Investig. 2012;59:225–34.

    Article  Google Scholar 

  35. El-Bawab HY, Abouzied MM, Rafay MA, et al. Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence. Interact Cardiovasc Thorac Surg. 2010;11:395–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

    Florian C. Gaertner

Authors
  1. Florian C. Gaertner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian C. Gaertner .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Klinikum Westfalen - Knappschaftskrankenhaus Academic teaching hospital of the Ruhr University, Dortmund, Nordrhein-Westfalen, Germany

    Hojjat Ahmadzadehfar

  2. Department of Nuclear Medicine, Beta Klinik Bonn, Bonn, Germany

    Hans-Jürgen Biersack

  3. Division of Nuclear Medicine, Department of Radiology, Montefiore Medical Center, Bronx, NY, USA

    Leonard M. Freeman

  4. Albert Einstein College of Medicine, Bronx, NY, USA

    Lionel S. Zuckier

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gaertner, F.C. (2020). PET in Lung Cancer and Mediastinal Malignancies. In: Ahmadzadehfar, H., Biersack, HJ., Freeman, L., Zuckier, L. (eds) Clinical Nuclear Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-39457-8_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-39457-8_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-39455-4

  • Online ISBN: 978-3-030-39457-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation